title: Linezolid therapy for infective endocarditis.
abstract: Linezolid is not yet recognised as a standard therapy for infective endocarditis. This report describes nine patients with endocarditis treated with linezolid and 33 similar cases from the medical literature. The majority of cases involved multiresistant strains, and the reasons for administering linezolid were refractory disease (60%), intolerance (28%), sequential therapy (12%) and a resistant pathogen (1%). Linezolid was administered for a mean of 37 days, with a successful outcome in 79% of cases. Reversible adverse effects were described in ten cases. The mean follow-up period was 8.5 months. Further data from randomised controlled clinical trials are needed to determine the efficacy and safety of linezolid for treating endocarditis.
authors.affiliation: Department of Clinical Microbiology-Infectious Diseases, Madrid, Spain. Electronic address: pmunoz@micro.hggm.es.
authors.forename: P
authors.initials: P
authors.lastname: Muñoz
authors.affiliation: Department of Clinical Microbiology-Infectious Diseases, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez-Creixéms
authors.affiliation: Department of Cardiology and Internal Medicine, Hospital General Universitario Gregorio Marañón, University of Madrid, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Moreno
authors.affiliation: Department of Clinical Microbiology-Infectious Diseases, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Marín
authors.affiliation: Department of Cardiology and Internal Medicine, Hospital General Universitario Gregorio Marañón, University of Madrid, Madrid, Spain.
authors.forename: V
authors.initials: V
authors.lastname: Ramallo
authors.affiliation: Department of Clinical Microbiology-Infectious Diseases, Madrid, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Bouza
authors.lastname: Game Study Group
mesh_terms: D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007223:Infant; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid